JP2006500346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500346A5 JP2006500346A5 JP2004527018A JP2004527018A JP2006500346A5 JP 2006500346 A5 JP2006500346 A5 JP 2006500346A5 JP 2004527018 A JP2004527018 A JP 2004527018A JP 2004527018 A JP2004527018 A JP 2004527018A JP 2006500346 A5 JP2006500346 A5 JP 2006500346A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- effective amount
- warm
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 28
- 241001465754 Metazoa Species 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000005865 ionizing radiation Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000001772 anti-angiogenic effect Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000001603 reducing effect Effects 0.000 claims 4
- 230000008728 vascular permeability Effects 0.000 claims 4
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0218526.2A GB0218526D0 (en) | 2002-08-09 | 2002-08-09 | Combination therapy |
| PCT/GB2003/003390 WO2004014426A1 (en) | 2002-08-09 | 2003-08-05 | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500346A JP2006500346A (ja) | 2006-01-05 |
| JP2006500346A5 true JP2006500346A5 (enExample) | 2006-08-31 |
Family
ID=9942013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004527018A Pending JP2006500346A (ja) | 2002-08-09 | 2003-08-05 | 癌の処置のためのｖｅｇｆ受容体チロシンキナーゼ阻害剤の組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050245549A1 (enExample) |
| EP (1) | EP1534338A1 (enExample) |
| JP (1) | JP2006500346A (enExample) |
| KR (1) | KR20050059060A (enExample) |
| CN (1) | CN100556456C (enExample) |
| BR (1) | BR0313117A (enExample) |
| CA (1) | CA2495489A1 (enExample) |
| GB (1) | GB0218526D0 (enExample) |
| IL (1) | IL166625A0 (enExample) |
| MX (1) | MXPA05001457A (enExample) |
| NO (1) | NO20050528L (enExample) |
| NZ (1) | NZ537754A (enExample) |
| WO (1) | WO2004014426A1 (enExample) |
| ZA (1) | ZA200501061B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100376567C (zh) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US7160889B2 (en) | 2000-04-07 | 2007-01-09 | Astrazeneca Ab | Quinazoline compounds |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| CN1625555A (zh) | 2002-02-01 | 2005-06-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| US7462623B2 (en) | 2002-11-04 | 2008-12-09 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
| DK1592423T3 (da) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| US20060167027A1 (en) * | 2003-07-10 | 2006-07-27 | Wedge Stephen R | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| MX2007003505A (es) * | 2004-09-27 | 2007-05-10 | Astrazeneca Ab | Combinacion que comprende zd6474 e imatinib. |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| MX2007012662A (es) * | 2005-04-14 | 2008-04-04 | Wyeth Corp | Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib. |
| JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| EP1948179A1 (en) | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| DE602006020621D1 (de) * | 2005-12-22 | 2011-04-21 | Astrazeneca Ab | Kombination von zd6474 und pemetrexed |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| BRPI0717586A2 (pt) * | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
| PL2451445T3 (pl) | 2009-07-06 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| GB201516905D0 (en) * | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| AU2002223684A1 (en) * | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| BR0309226A (pt) * | 2002-04-16 | 2005-02-09 | Astrazeneca Ab | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| US20050222183A1 (en) * | 2002-08-09 | 2005-10-06 | Wedge Stephen R | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| DK1592423T3 (da) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11 |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| US20060167027A1 (en) * | 2003-07-10 | 2006-07-27 | Wedge Stephen R | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| MX2007003505A (es) * | 2004-09-27 | 2007-05-10 | Astrazeneca Ab | Combinacion que comprende zd6474 e imatinib. |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| DE602006020621D1 (de) * | 2005-12-22 | 2011-04-21 | Astrazeneca Ab | Kombination von zd6474 und pemetrexed |
-
2002
- 2002-08-09 GB GBGB0218526.2A patent/GB0218526D0/en not_active Ceased
-
2003
- 2003-08-05 EP EP03784248A patent/EP1534338A1/en not_active Withdrawn
- 2003-08-05 KR KR1020057002187A patent/KR20050059060A/ko not_active Ceased
- 2003-08-05 NZ NZ537754A patent/NZ537754A/en not_active IP Right Cessation
- 2003-08-05 MX MXPA05001457A patent/MXPA05001457A/es active IP Right Grant
- 2003-08-05 BR BR0313117-3A patent/BR0313117A/pt not_active IP Right Cessation
- 2003-08-05 CA CA002495489A patent/CA2495489A1/en not_active Abandoned
- 2003-08-05 JP JP2004527018A patent/JP2006500346A/ja active Pending
- 2003-08-05 WO PCT/GB2003/003390 patent/WO2004014426A1/en not_active Ceased
- 2003-08-05 US US10/523,838 patent/US20050245549A1/en not_active Abandoned
- 2003-08-05 CN CNB038191105A patent/CN100556456C/zh not_active Expired - Fee Related
-
2005
- 2005-01-31 NO NO20050528A patent/NO20050528L/no not_active Application Discontinuation
- 2005-02-01 IL IL16662505A patent/IL166625A0/xx unknown
- 2005-02-04 ZA ZA200501061A patent/ZA200501061B/en unknown
-
2009
- 2009-07-13 US US12/501,593 patent/US20100130493A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006504723A5 (enExample) | ||
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| JP2005511597A5 (enExample) | ||
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| BR0313117A (pt) | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| JP2006502132A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| WO2006035204A3 (en) | Combination comprising zd6474 and an imatinib | |
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| JP2005530735A5 (enExample) | ||
| ATE353650T1 (de) | Kombinationstherapie zur behandlung von krebs | |
| CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine |